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Abstract
Background: With numerous and fast approvals of different agents including immune checkpoint inhibitors,
monoclonal antibodies, or chimeric antigen receptor (CAR) T-cell therapy, immunotherapy is now an established
form of cancer treatment. These agents have demonstrated impressive clinical activity across many tumor types,
but also revealed different toxicity profiles and mechanisms of action. The classic assumptions imposed by
cytotoxic agents may no longer be applicable, requiring new strategies for dose selection and trial design.
Description: This main goal of this article is to summarize and highlight main challenges of early-phase study design
of immunotherapies from a statistical perspective. We compared the underlying toxicity and efficacy assumptions of
cytotoxic versus immune-oncology agents, proposed novel endpoints to be included in the dose-selection process,
and reviewed design considerations to be considered for early-phase trials. When available, references to software
and/or web-based applications were also provided to ease the implementation. Throughout the paper, concrete
examples from completed (pembrolizumab, nivolumab) or ongoing trials were used to motivate the main ideas
including recommendation of alternative designs.
Conclusion: Further advances in the effectiveness of cancer immunotherapies will require new approaches that
include redefining the optimal dose to be carried forward in later phases, incorporating additional endpoints in
the dose selection process (PK, PD, immune-based biomarkers), developing personalized biomarker profiles, or
testing drug combination therapies to improve efficacy and reduce toxicity.
Keywords: Immunotherapy, Early-phase, Clinical trials
Background
The advent of the breakthrough therapy designation for
experimental drugs by the Food and Drug Administration
(FDA), initiated as part of the FDA Safety and Innovation
Act (FDASIA) in July 2012, has taken oncology drug de-
velopment in a new direction. A therapy receives this
FDA designation if it is “one which is intended alone or in
combination to treat a serious or life-threatening disease
or condition, and for which preliminary clinical evidence
indicates the drug may demonstrate substantial im-
provement over existing therapies on one or more clinic-
ally significant endpoints” [1, 2]. Such a designation from
the FDA accelerates the review and development process
of the new therapy, prompting regular communication
between the FDA and the sponsor to guide the develop-
ment of promising agents. Since the FDASIA was signed
into law, there have been several accelerated approvals of
cancer drugs, particularly immune-oncology agents. For
example, the immune checkpoint inhibitor pembrolizu-
mab was FDA-approved for the treatment of melanoma in
December 2014, three months after publication of the
Phase I data [3]. Approval was based on the results from a
dose-comparing, activity-estimating cohort within a multi-
center open-label randomized phase 1b clinical trial. The
major efficacy endpoint was confirmed overall response
rate. As a condition of this accelerated approval, Merck
was required to conduct a multicenter randomized trial
establishing the superiority of pembrolizumab over stand-
ard therapy to verify and describe its clinical benefit.
These accelerated approvals have led to a substantial in-
crease in the number of clinical trials testing immunother-
apies. The efficacy exhibited by checkpoint inhibitors in
melanoma patients [4–6] triggered further testing in other
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cancer subtypes such as non-small cell lung cancer [7, 8],
renal cell cancer [9, 10], bladder cancer [11], and Hodgkin
Lymphoma [12]. Other immune-oncology treatment strat-
egies include monoclonal antibodies, cancer vaccines, and
adoptive T-cell therapies such as chimeric antigen recep-
tor (CAR)-modified T-cells.
The changing landscape of oncology drug development
has resulted in a significant departure from the historical
paradigm of a clinical trial design, especially in early devel-
opment. Phase I trials have served as initial safety studies,
with the main objective of identifying the maximum toler-
ated dose (MTD). The MTD is the highest dose among a
range of predefined dose levels that satisfies some safety
requirement. The underlying assumption driving the de-
sign of a Phase I trial is that both the risk of toxicity and
the probability of clinical benefit increase with dose level;
thus, the MTD represents the most promising dose for ef-
ficacy. The primary toxicity endpoint of interest is most
often a binary one, defined in terms of the proportion of
patients who experience a dose-limiting toxicity (DLT;
yes/no), based on protocol-specific adverse event defi-
nitions. The definition of DLT will be defined at the de-
sign stage and will differ from trial to trial, depending
on disease specification and agent being tested. It typically
is characterized by a grade 3 or higher adverse event ac-
cording to the National Cancer Institute (NCI) Common
Terminology Criteria (CTCAE) in the first cycle of treat-
ment. The primary objective is to locate the MTD, defined
as highest dose that can be administered to and tolerated
by an acceptable proportion of patients. The MTD is often
the recommended Phase II doses (RP2D) under the as-
sumption that higher doses are likely to be more effective.
While the traditional approach to Phase I clinical trial
designs is adequate for testing cytotoxic agents (e.g.,
chemotherapy), immune-oncology agents have different
assumptions and challenges, some of which may also be
applicable to targeted therapies. Thus, trial designs and
the corresponding endpoints need to be adapted to the
specific agents being investigated [13, 14]. There is a
growing need for the implementation of new study de-
signs that address the clinical realities and statistical
considerations arising from these new treatment para-
digms. In this article, we discuss some of the statistical
challenges that immune-oncology agents pose to widely-
accepted methods used in early-phase clinical trials, and
make recommendations for implementing innovative trial
designs in future studies facing these challenges (Table 1).
Design challenges and recommendations
Late-onset toxicities
Dosing decisions in Phase I trials have traditionally been
guided by DLTs that occur in cycle 1 of treatment, which
is generally 28 days long. In these trials, MTDs are de-
fined as the highest tolerated dose from cycle 1, even
though patients are administered therapy over the course
of several cycles. This approach was appropriate for cyto-
toxic chemotherapy agents, which generally cause DLTs to
be observed early in the treatment course. However, acute
toxicity does not provide a complete representation of
tolerability for immune-oncology agents. These new agents
are administered over extended periods of time, which can
result in immune-related adverse events (irAEs) occurring
outside of a short-term evaluation window. For example,
in a pooled analysis of 576 patients with advanced melan-
oma who received nivolumab, the median onset time of
various treatment-related adverse events of any grade
ranged from 5.0 weeks for skin toxicities to 15.1 weeks for
renal toxicities [15]. For patients treated with pembrolizu-
mab, the median onset time of irAEs has varied from
1.3 months for hepatitis to 3.5 months for diarrhea [16].
Therefore, the assessment of appropriate doses based solely
on DLT definitions from cycle 1 toxicity outcomes is
insufficient for immune-oncology therapies. One pos-
sible solution to this limitation, which has been utilized
in several recently published studies of immune-oncology
agents [17–20], is to extend the DLT evaluation window.
Additionally, to identify more appropriate doses for further
research, there is a growing need to incorporate richer
toxicity information beyond DLTs observed in cycle 1.
The most well-known dose-finding method that allows
for the incorporation of late toxicities into the design is
the time-to-event continual reassessment method (TITE-
CRM) [21]. This method utilizes information from partially
observed subjects throughout the trial, without staggering
enrollment. In the absence of a DLT, it weights each en-
tered patient by the proportion of the full observation
period that he/she has been observed. In the case of no
DLTs outside the observation window, the method reduces
to the original continual reassessment method (CRM) [22].
Given the availability of R packages (dfcrm) and SAS tools
(https://sph.umich.edu/ccb/tite-resources.html) for simu-
lating and conducting the TITE-CRM, the method can
be easily tested and implemented into studies in which
late-onset DLTs are anticipated. Another recently
published method adapts the Bayesian Optimal Interval
(BOIN) design to handle late-onset DLTs, and it is
accompanied by a user-friendly web application at
www.trialdesign.org [23].
More may not be better
The monotonicity assumption in the traditional Phase I
setting is driven by the notion that cytotoxic chemother-
apy treatments will directly inhibit the growth of malig-
nant cells, and that the MTD will provide the greatest
therapeutic benefit. Conversely, immune-oncology agents
generally do not directly impact malignant cells. Instead,
immune cells, such as T-cells or natural killer cells, indir-
ectly facilitate the cytotoxic efficacy of these agents. The
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notion that “more is better” for efficacy and “more is worse”
for toxicity may not hold true for immune-oncology agents,
thus violating the monotonicity assumption that historically
underlain Phase I trial designs. Consequently, the early de-
velopment of immune-oncology agents may need to transi-
tion from identifying the MTD to identifying the minimum
effective dose. In the case of a dose-efficacy curve that
plateaus beyond a certain dose, the optimal dose may
fall below the MTD and application of an MTD-based
approach could lead to incorrect dosing. For example,
in a study of nivolumab, no MTD was reached for doses
of 1, 3, and 10 mg/kg using the original 3 + 3 design. How-
ever, based on initial signs of activity, additional expansion
cohorts were added at doses far below the MTD (0.1 and
0.3 mg/kg), indicating a flat dose-efficacy curve among
the dose being considered [5]. The dose-toxicity and
dose-efficacy relationships for anti-PD-1/PD-L1 therapies
remain unclear, with relatively flat toxicity and efficacy
rates for doses ranging from 1 to 2 mg/kg to 20 mg/kg
every 2 or 3 weeks [17, 18, 24]. Conversely, based on re-
sults from a study of ipilimumab, patients treated with
10 mg/kg demonstrated better overall survival than those
treated with 3 mg/kg (15.7 months (95% confidence inter-
val [CI] 11.6–17.8) versus 11.5 months (95% CI 9.9–13.3)
(hazard ratio [HR] 0.84; p = 0.04)) [25]. The patients
treated with 10 mg/kg also had a higher rate of irAEs
than those treated with 3 mg/kg [20], indicating dose-
dependent toxicity and efficacy relationships for ipili-
mumab. As for toxicity, early-phase data were exten-
sively studied in a review of thirteen Phase I clinical
trials of immune checkpoint blocking antibodies [26].
In this review, only one trial identified protocol-defined
DLTs [27]. In most of the other trials, the RP2D was
based upon the maximum administered dose, which in
turn is based on a pre-specified dose range developed
from pharmacokinetic data.
Implementation of novel approaches that incorporate
multiple endpoints are needed to establish and refine
the choice of recommended Phase II doses. In addition
to a DLT endpoint, early-phase design strategies should
incorporate a tumor activity endpoint, with the goal of
identifying an effective dose [7, 28]. Activity markers may
include early measures of efficacy (e.g., clinical response),
altered pharmacokinetics, altered pharmacodynamic out-
comes, and a persistent immune response. The field of
immune-oncology often investigates treatments that
demonstrate minimal overall toxicity, wherein higher doses
may not induce a greater response. The treatment response
may increase at low doses and then begin to plateau at
higher doses. The goal of the trial then becomes identifying
the optimal biologically active dose (OBD), defined as a safe
dose that demonstrates the greatest pharmacological activity.
In recent years, several new methods have been proposed
for identifying the optimal safe and effective dose in Phase
I-II trials [29, 30]. For the problem of locating the optimal
biologic dose based on toxicity and activity endpoints in
single-agent trials, web applications exist for simulation and
implementation of the Wages and Tait [30] method at
https://uvatrapps.shinyapps.io/wtdesign/ and for the Zang,
Lee, and Yuan [29] method at www.trialdesign.org. One ad-
vantage of the Wages and Tait app is the ability of the user
to incorporate a stopping rule that terminates the study
once a pre-specified maximum number of patients have
been accrued to one of the dose levels.
Drug combinations
It is becoming increasingly popular to treat patients with
combination immunotherapy due to the potential for
synergistic activity in which the efficacy of both agents
together is higher than the efficacy of each agent alone,
hopefully without significantly increasing toxicity. The
selection of appropriate drug combinations for testing can
be very challenging because single agent toxicity data may
not be sufficient for characterizing the safety profile of the
combination. The most effective and safest doses in
drug combinations are seldom the same as those of the
individual agents identified in monotherapy trials [31].
Drug combination dose-finding trials also present a greater
challenge of finding an MTD combination, or combina-
tions, due to the more complex toxicity and efficacy pro-
files presented by the potential interaction of the two
agents. For example, it is recommended that, combinations
of drugs with non-overlapping toxicity profiles be devel-
oped whenever possible, since overlapping toxicities can
limit escalation of the combination doses to effective
levels. In the case of non-overlapping toxicities, the
DLT definition of the drug combination is specific to
the agents being studied. In practice, Phase I drug
combination studies necessitate significant planning at
the design stage in order to establish the starting dose
of each agent and the total number of combinations to
be tested, and these studies can rapidly grow in sample
size and cost [32].
In addition to the complexities mentioned above, drug
combination studies present additional design challenges
to those encountered in single agent studies. Because of
the monotonicity assumption, single-agent trials are said
to follow a complete order. This is because the ordering
of DLT probabilities for any pair of doses is known, and
administration of greater doses of the agent can be ex-
pected to produce DLT’s in increasing proportions of
patients. The monotonicity assumption lends itself to
escalation along a single line of doses. Given the toxicity
response (DLT; yes/no) for a particular patient, either the
same dose is recommended for the next patient or the
dose is changed to one of two adjacent doses (i.e. either
escalate to the next highest dose or de-escalate to the
next lowest dose). In studies testing drug combinations,
Wages et al. Journal for ImmunoTherapy of Cancer  (2018) 6:81 Page 4 of 10
the probabilities of DLTs often follow a “partial order”
meaning that there are pairs of combinations for which
the ordering of the probabilities is unknown. In a multi-
agent trial, there will most likely be more than one pos-
sible treatment with which to treat the next patient cohort
in a decision of escalation, and it may not be clear as to
which combination to the next cohort should receive.
A traditional approach to this combination dose-find-
ing is to pre-select drug combinations with a known tox-
icity order and apply a single-agent design by escalating
and de-escalating doses along a chosen path [33]. This
could be done by, a priori, pre-specifying a subset of
combinations for which the toxicity ordering is known.
This approach transforms the two-dimensional
dose-finding space into a one-dimensional space, and it
has been used in much of the early work in dose combi-
nations [34, 35]. The disadvantage of this approach is
that it limits the number of dose combinations that can
be considered and it can potentially miss promising dose
combinations that exist outside of the path. More re-
cent methods have moved away from reducing the
two-dimensional dose-finding space to a single dimen-
sion, a thorough review of which has been written by
Harrington et al. [36]. A number of designs have been
proposed for finding the MTD of cytotoxic agents [37–39].
These methods determine combinations to which patients
are allocated based solely on toxicity considerations, with-
out accounting for efficacy. As in the single-agent setting,
these model-based methods have superior performance to
rule-based methods in terms of accuracy of MTD identifi-
cation, and safety in allocating patients [32]. A web applica-
tion for the Bayesian Optimal Interval (BOIN) method [39]
for combinations is available at www.trialdesign.org, and R
packages exist for the partial order continual reassess-
ment method (package pocrm) [37] and the product of
independent beta probabilities escalation (PIPE) design
(package pipe.design) [38]. The POCRM was successfully
implemented in a recently completed, but yet to be pub-
lished, Phase I trial designed to determine the MTD of a
combination of a toll-like receptor (TLR) agonists with or
without a form of incomplete Freund’s adjuvant (IFA) for
the treatment of melanoma (NCT01585350). To our
knowledge, the PIPE design has been implemented in
two dose-finding studies (NCT02760797, NCT02308072).
There are a few existing early-phase designs for drug com-
bination trials that account for both toxicity and efficacy.
For example, the method of Wages and Conaway [40] has
been adapted and implemented in recently completed and
ongoing early-phase studies of combination immune-on-
cology agents (NCT02126579, NCT02425306) [41, 42]
using immunologic response as a binary activity endpoint
for driving the design. The R code used to successfully
implement these designs are available at http://faculty.
virginia.edu/model-based_dose-finding/.
The methods recommended in this section can broadly
be implemented in early-phase combination studies that
involve immunotherapies in combination with other im-
munotherapies, or in combination with chemotherapy,
radiotherapy, or molecularly targeted agents. Each of these
combination types may present their own specific set of
trial design challenges, but the methodology described can
be generally adapted and applied to meet the research ob-
jectives of a broad range of early-phase combination stud-
ies. As highlighted at the 2018 ASCO annual meeting,
more work is needed in acquiring a better understanding
of how to optimally combine therapies [43]. As we learn
more, early-phase methodology may need to be adapted
to handle unique design challenges associated with novel
treatment combinations involving immunotherapies.
Dose and schedule
The lack of a clear dose-efficacy relationship for both
anti-CTLA-4 and anti-PD-1 antibodies has resulted in
these agents being assessed at various dose-schedule
combinations. For example, ipilimumab was evaluated in
four Phase I trials at doses ranging from 3 mg/kg to
20 mg/kg, without an MTD being identified in any of
the trials. A subsequent Phase II trial compared three
dose levels of ipilimumab in patients with metastatic
melanoma (0.3, 3, and 10 mg/kg); this trial, along with a
positive Phase III experience at 3 mg/kg, yielded the
registration dose of 3 mg/kg for 4 cycles [44]. Concur-
rently, patients with resected melanoma were enrolled in
a study using adjuvant ipilimumab at a higher dose
(10 mg/kg) and with an alternative schedule (4 cycles
every 3 weeks with maintenance doses every 3 months).
This dose and schedule was FDA- approved in the adju-
vant setting after it was shown to improve progression
free survival [45].
Pembrolizumab has also been studied at different
doses (2 mg/kg vs 10 mg/kg) and different schedules
without a significant difference in efficacy or toxicity by
dose or schedule [3, 46]. More recently, flat dosing of
pembrolizumab at 200 mg every 3 weeks has been FDA
approved for the treatment of squamous cell carcinoma
of the head and neck and PD-L1 positive NSCLC [47, 48].
Further contributing to the uncertainty of dosing design is
the use of alternative schedules when immune checkpoint
inhibitors are used in combination. For example, the com-
bination of nivolumab 1 mg/kg and ipilimumab 3 mg/kg
dosed every 3 weeks for 4 doses is FDA-approved for the
treatment of metastatic melanoma [49, 50]. Alternative
dosing of the combination of nivolumab and ipilimumab
was studied in a Phase I trial of patients with metastatic
NSCLC in which patients were randomized to receive
nivolumab 1 mg/kg every 2 weeks plus ipilimumab
1 mg/kg every 6 weeks, nivolumab 3 mg/kg every
2 weeks plus ipilimumab 1 mg/kg every 12 weeks, or
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nivolumab 3 mg/kg every 2 weeks plus ipilimumab
1 mg/kg every 6 weeks. Response rates and irAEs were
similar in the two treatment groups that received nivo-
lumab 3 mg/kg and both of these arms are considered
promising for further study in the randomized Phase 3
trial Checkmate 227 [51].
For these trials, finding an acceptable dose and sched-
ule becomes a two-dimensional dose-finding problem,
wherein one dimension is the dose level of the agent and
the other dimension is the schedule of therapy. In address-
ing this type of problem, the approach of Braun et al. [52]
based on a time-to-toxicity endpoint, was used to design a
dose and schedule finding study (NCT00350818) of de
Lima et al. [53]. Available software can be accessed at
https://biostatistics.mdanderson.org/softwaredownload/
SingleSoftware.aspx?Software_Id=75. Wages, O’Quigley
and Conaway [54] proposed a method for finding a
maximum tolerated dose-schedule combination, based
on a binary toxicity endpoint, and the R package
(pocrm) can be applied to this setting.
Further challenges
Novel endpoints in phase I trials
Under the new assumptions of milder, non-monotone
toxicity profiles, determining the OBD is an attractive
goal for the early-phase studies. Practically speaking,
dose-finding studies incorporating multiple (biological)
endpoints have become frequently used approaches for
evaluation of targeted, non-cytotoxic drugs. However,
there are several barriers that limit their potential to just
exploratory endpoints. The inclusion of biological end-
points and determination of an optimal dose based on
some biomarker occurrence should rely on pre-specified
thresholds such as targeted plasma or blood drug con-
centration, or other immunologic parameter. Incorporat-
ing PK information in the dose finding process can
provide a better estimation of the dose-toxicity curve
while maintaining the performance in terms of MTD se-
lection. However, in most phase I trials, the dose-finding
and pharmacokinetics (PK) analyses are considered sep-
arately, which for small populations might impact the es-
timation of both the toxicity and PK parameters. Ursino
et al. [55] developed and extended methods that take into
account PK measurements in sequential Bayesian adaptive
early-phase designs. Several models including PK mea-
sures either as a covariate or as a dependent variable
are examined via simulations in terms of MTD percent
correct selection (PCS) and the ability to estimate the
dose-response curve. Operating characteristics are pre-
sented for a fixed sample size of 30 subjects, six
pre-defined dose levels, and seven toxicity scenarios.
The main conclusion is that good prior knowledge about
PK can help reduce the percentage of overdosing without
altering the MTD selection. Still, some of the methods
presented (e.g., PKCRM) rely heavily on the choice of PK
constraints which in some cases fail to achieve the true
MTD. These adaptive pharmacokinetics-based dose-
finding designs can be implemented using the R package
(dfpk) [56]. Assessing pharmacodynamic (PD) markers as
primary endpoints can also be challenging, as they not only
require a strong scientific rationale, but also a non-invasive
reproducible assay that can track PD markers with minimal
harm to the patient [57]. Integration of clinical PK and
pre-clinical PD has provided an additional modality of aug-
menting early clinical data with animal data, but nothing is
relevant in the absence of definitive correlations between
the target inhibition in PK or PD biomarkers and clinical
efficacy (e.g., tumor response).
Adoptive T cell therapy is a rapidly emerging immuno-
therapeutic approach that consists of an infusion of gen-
etically engineered T cells that express a specific antigen
on their cell membrane. In 2017, based on a pivotal
Phase II trial, the FDA approved the first chimeric anti-
gen receptor (CAR-T) cell therapy (tisagenlecleucel) for
children and young adults with B-cell ALL in a popula-
tion with limited treatment and poor outcomes [58].
With 83% remission rate, this therapy has demonstrated
early and durable response, but much remains to be
learned regarding cell proliferation, persistence and
mechanisms of relapse. An important predictor of the
efficacy of CAR–T cells is their ability to expand in vivo
in response to recognition of CD19+ target cells, and
therefore, patients that failed to respond in prior studies
typically had poor accumulation of CAR–T cells. Inter-
estingly, a recent study investigating CD19 CAR–T cells
demonstrated a correlation between cell dose levels
(magnitudes of 105 cells/kg), earlier/higher peak expan-
sion and clinical response [59]. This finding was also
seen in other studies that showed direct correlations be-
tween the number of transduced T cells and antitumor
response [60], or correlation between clinical response
and persistence of administered cells at one month [61].
Although CD19 CAR-T cells showed a therapeutic effect
in patients with relapsed and refractory B-cell ALL, sig-
nificant toxicities have occurred, especially after infusion
of higher CAR-T cell doses. Data imply that an optimal
dosing strategy to minimize toxicity would be to initially
give low CAR-T cell dose to patients with higher tumor
burden, whereas those with low tumor burden may re-
quire higher or repeated doses. Thus, under this para-
digm shift, dose-finding trials driven solely by toxicity is
no longer realistic. Early phase trials should start incorp-
orating more immunological information, while still
maintaining acceptable toxicity levels.
The majority of current trials include extended correla-
tive studies, in order to identify promising biomarkers
from investigation of immunologic factors of the tumor or
tumor microenvironment. Immunologic characteristics
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within the peripheral blood may similarly help predict
outcomes following immunotherapy and allow for im-
munologic monitoring (T-cell response or percent per-
sistence of transduced T-cells) while on treatment. New
dose-finding designs have proposed independent or
joint modelling of toxicity and immunological out-
comes, both in binary and continuous forms [62]. Also,
multi-stage adaptive designs have become more fre-
quent in the early stages of development, with patients
being randomized towards doses with higher predicted
efficacy. In the context of personalized medicine, im-
munotherapy is becoming more and more relevant, es-
pecially for establishing the patient’s immune system
profile and developing a tailored treatment/scheduling
regimen.
Expansion cohorts
Phase I trials often include a dose expansion phase with
one or more dose expansion cohorts (DEC) after com-
pletion of dose escalation with an overall goal to further
characterize toxicity, gain preliminary evidence of efficacy,
and/or determine the RP2D. It has become common
practice that Phase I studies of immuno-oncology agents
include multiple DECs based on specific molecular char-
acteristics, biomarker and/or disease type.
The goals of the DEC will drive the sample size of the
cohort(s). If the objective is to gain a more precise esti-
mate of the probability of toxicity as has been the con-
ventional purpose of DEC, then expansion cohorts are
based on a pre-specified number of patients (e.g., 5, 10,
15) treated at MTD. When less than 15 patients are tar-
geted for each DEC, formal sample size justification may
not be feasible. The resulting RP2D may differ from the
MTD as additional toxicity data are gathered through
the expansion phase. In one systematic review, among
expansion cohorts with safety objectives, new toxicities
were reported in 54% of trials and the R2PD was modi-
fied in 13% [63]. Re-evaluation of toxicity data after
DECs is increasingly important for the safety assessment
of checkpoint inhibitors given that adverse events can
occur weeks to months after treatment. Approaches for
incorporating the additional information include: combin-
ing the toxicity data from the initial dose escalation and
DEC after all patients have been treated; re-evaluation of
the MTD as data from the expansion cohort are obtained
with safety stopping rules built-in; evaluation of the MTD
incorporating both safety and efficacy; and evaluation of
MTD for different sub-populations [64]. Simulation stud-
ies have demonstrated that failure to include toxicity out-
comes from DECs can result in less accurate estimate of
the MTD [63].
Given the advances in technology and in our under-
standing of tumor biology which have allowed for sig-
nificantly more drug and drug combinations tested
simultaneously, the need for DECs to assess antitumor
activity earlier in the drug development has resulted in
projected accruals of the DEC to mimic traditional
Phase II sample sizes, per cohort [65, 66]. In this setting,
when assessment of efficacy is the primary objective for
the DEC, a formal sample size justification with power cal-
culation is recommended along with pre-defined stopping
rules for futility to avoid exposing a high number of pa-
tients to the risk of ineffective or potentially dangerous
treatment.
However, justification of sample sizes can be difficult
and has led to very large studies in immune oncology
and not always a clear rationale upfront. The anti-PD-L1
compound avelumab is being studied in a Phase I trial
with 16 expansion cohorts with a total projected enroll-
ment of 1706 people. In 2011, Merck initiated a first-in-
human trial to determine the safety and recommended
dose of pembrolizumab in patients with advanced solid
tumors (NCT01295827, NCT01772004) [3]. This Phase I
trial ultimately enrolled more than 1200 patients. Impres-
sive response rates and duration of response were ob-
served in patients with metastatic melanoma and non–
small cell lung cancer, resulting in the addition of DECs to
assess efficacy in these two patient populations, evaluate
alternative dosing regimens and candidate predictive bio-
markers [67]. Although the 1000+ patient Phase I trial is
not typical, inclusion of many DECs have become stand-
ard and in some ways replacing the traditional clinical trial
sequence.
Discussion
Clinical practice has rapidly incorporated immune-
oncologic agents into the standard treatment and manage-
ment of many cancers. In general, immunotherapy is a
treatment modality that activates the immune system to
eliminate cancer rather than attacking cancer cells directly.
The clinical success of immunotherapy has challenged the
existing paradigm for clinical research. With standard
chemotherapy or molecularly targeted agents, clinical bene-
fit usually occurs during active treatment and does not per-
sist after treatment discontinuation unlike immunotherapy.
Decades of rigorous evaluation through early and late phase
clinical trials has informed the understanding and manage-
ment of the short and long-term effects of toxicities from
chemotherapy. However, less is known regarding the toxic-
ities associated with immunotherapy.
Due to the activation of the immune system, immune-
oncologic agents can inadvertently activate the immune
system against self, resulting in significant immune-related
adverse events [68]. Since serious immune-related adverse
events represent immune activation, they may actually re-
flect therapeutic benefit. Furthermore, while low grade
immune-related adverse events are managed with dose re-
ductions, management of more severe adverse events
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includes administration of anti-inflammatory therapies
such as corticosteroids, infliximab or mycophenolate to
dampen immune activation [68, 69], potentially weakening
therapeutic benefit.
Understanding the mechanisms of response and ad-
verse events in the context of these agents is critical for
the selection of appropriate clinical trial designs. Ac-
cording to the Institute for Clinical Immuno-Oncology
between 2006 and 2014, the number of clinical trials
registered on ClinicalTrials.gov increased from 9321 to
18,400 [70]. According to the “Medicines in Development
for Immuno-Oncology 2017 Report,” from PhRMA in
partnership with the American Cancer Society Action Net-
work (ASCAN), more than 248 new immuno-oncologic
agents are currently in clinical trials or awaiting U.S. FDA
review [71]. In addition, from 2015 to 2017, the number of
combination studies listed on ClinicalTrials.gov combining
PD-1 or PD-L1 inhibitors with other therapies has more
than tripled from 215 to 765 (combination trials with pem-
brolizumab [n = 268]; nivolumab [n = 242]; durvalumab
[n = 123]; atezolizumab [n = 83]; avelumab [n = 18]; and
others [n = 49]) [72]. Implementation of innovative design
strategies in the early development of combination im-
munotherapies is critical to delivering more effective ther-
apies with improved outcomes.
In this paper, we reviewed design considerations for
early phase clinical trials of immuno-oncology agents
and when available provided reference to software for
applicability of these designs. There is increasing de-
mand for study designs that are best suited and optimal
in this setting. A deeper understanding of clinically
meaningful endpoints, characterization of toxicity, iden-
tification of immune parameters and mutational burden
to help guide patient selection will allow for the further
development of novel designs for early phase trials of
immuno-oncologic agents.
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